These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 22262762)

  • 41. The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
    Blume R; Rempel E; Manta L; Saeed BR; Wang W; Raffel S; Ermakova O; Eckstein V; Benes V; Trumpp A; Ho AD; Lutz C
    Leuk Lymphoma; 2018 Sep; 59(9):2201-2210. PubMed ID: 29334844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CD34
    Zeijlemaker W; Grob T; Meijer R; Hanekamp D; Kelder A; Carbaat-Ham JC; Oussoren-Brockhoff YJM; Snel AN; Veldhuizen D; Scholten WJ; Maertens J; Breems DA; Pabst T; Manz MG; van der Velden VHJ; Slomp J; Preijers F; Cloos J; van de Loosdrecht AA; Löwenberg B; Valk PJM; Jongen-Lavrencic M; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2019 May; 33(5):1102-1112. PubMed ID: 30542144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
    Herrmann H; Kneidinger M; Cerny-Reiterer S; Rülicke T; Willmann M; Gleixner KV; Blatt K; Hörmann G; Peter B; Samorapoompichit P; Pickl W; Bharate GY; Mayerhofer M; Sperr WR; Maeda H; Valent P
    Curr Cancer Drug Targets; 2012 Jan; 12(1):51-63. PubMed ID: 22165967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Senescence effects of Angelica sinensis polysaccharides on human acute myelogenous leukemia stem and progenitor cells.
    Liu J; Xu CY; Cai SZ; Zhou Y; Li J; Jiang R; Wang YP
    Asian Pac J Cancer Prev; 2014 Jan; 14(11):6549-56. PubMed ID: 24377566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
    Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ
    Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.
    Kornblau SM; Qutub A; Yao H; York H; Qiu YH; Graber D; Ravandi F; Cortes J; Andreeff M; Zhang N; Coombes KR
    PLoS One; 2013; 8(10):e78453. PubMed ID: 24223100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.
    Pearce DJ; Taussig D; Simpson C; Allen K; Rohatiner AZ; Lister TA; Bonnet D
    Stem Cells; 2005; 23(6):752-60. PubMed ID: 15917471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High ALDHdim-expressing CD34+CD38- cells in leukapheresed peripheral blood is a reliable guide for a successful leukemic xenograft model of acute myeloid leukemia.
    Lee JY; Park S; Han AR; Lim J; Min WS; Kim HJ
    Oncol Rep; 2014 Oct; 32(4):1638-46. PubMed ID: 25069538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation.
    Miraki-Moud F; Anjos-Afonso F; Hodby KA; Griessinger E; Rosignoli G; Lillington D; Jia L; Davies JK; Cavenagh J; Smith M; Oakervee H; Agrawal S; Gribben JG; Bonnet D; Taussig DC
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13576-81. PubMed ID: 23901108
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic Impact and Phenotype of Residual Acute Myeloid Leukemia Stem Cells.
    Jaddaoui S; Bencharef H; Lamchahab M; Quessar A; Oukkache B
    Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of chronic myeloid leukemia stem cells.
    Gerber JM; Qin L; Kowalski J; Smith BD; Griffin CA; Vala MS; Collector MI; Perkins B; Zahurak M; Matsui W; Gocke CD; Sharkis SJ; Levitsky HI; Jones RJ
    Am J Hematol; 2011 Jan; 86(1):31-7. PubMed ID: 21132730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease.
    Risueño RM; Campbell CJ; Dingwall S; Levadoux-Martin M; Leber B; Xenocostas A; Bhatia M
    Blood; 2011 Jun; 117(26):7112-20. PubMed ID: 21562049
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [In Vitro Identification and Characteristics of CD34
    Zhang YH; Yang L; Wang YZ; Kong Y; Zhu HH; Qin YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1289-1294. PubMed ID: 29070097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.
    Snauwaert S; Vanhee S; Goetgeluk G; Verstichel G; Van Caeneghem Y; Velghe I; Philippé J; Berneman ZN; Plum J; Taghon T; Leclercq G; Thielemans K; Kerre T; Vandekerckhove B
    Haematologica; 2012 Oct; 97(10):1539-47. PubMed ID: 22532518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update of ALDH as a Potential Biomarker and Therapeutic Target for AML.
    Yang X; Yao R; Wang H
    Biomed Res Int; 2018; 2018():9192104. PubMed ID: 29516013
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia.
    Hoang VT; Hoffmann I; Borowski K; Zepeda-Moreno A; Ran D; Buss EC; Wuchter P; Eckstein V; Ho AD
    Methods Mol Biol; 2013; 1035():217-30. PubMed ID: 23959995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes.
    Gerber JM; Zeidner JF; Morse S; Blackford AL; Perkins B; Yanagisawa B; Zhang H; Morsberger L; Karp J; Ning Y; Gocke CD; Rosner GL; Smith BD; Jones RJ
    Haematologica; 2016 May; 101(5):607-16. PubMed ID: 26819054
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission.
    Feuring-Buske M; Haase D; Buske C; Hiddemann W; Wörmann B
    Leukemia; 1999 Mar; 13(3):386-92. PubMed ID: 10086729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.